Purpose: e purpose of this study was to analyze the e ects of estrogen de ciency and hormone replacement therapy (HRT) on brinolytic activity in a rat mode of surgicallyinduced menopause.
Due to the increase age of the global population, the proportion of women who spend up to one-third of their life in the postmenopausal period will increase, and they will be increasingly a ected by the consequences of menopausal hormonal changes [1] . Reports on the bene cial e ects of various combinations of postmenopausal estrogen/progesterone therapies on cardiovascular risk parameters such as the lipid pro le, lowdensity lipoprotein (LDL) oxidation, vascular function and the brinolysis/coagulation system are variable and contradictory [2] .
e bene cial e ects of hormone replacement therapy (HRT) are evident in the primary target tissues of menopausal therapy, such as bone, cardiovascular system, vagina and brain [3] . Fibrinolysis and coagulation during menopause, and the e ects of HRT on the delicate balance between them, are particularly important for risks of acute cardiovascular conditions, such as stroke, myocardial ischemia and infarction, and deep vein thrombosis, during the postmenopausal period.
Endogenous brinolysis is regulated predominantly by tissue plasminogen activator (tPA) through enzymatic conversion of plasminogen to plasmin. Plasma levels of active tPA are determined by the combined e ects of its synthesis from vascular endothelium [4) , binding to plasminogen activator inhibitor-1 (PAI-1) and other inhibitors [5] , and by hepatic clearance (6] . Elevated tPA antigen levels, which re ect both active free tPA and inert tPA bound in activator/inhibitor complexes, may indicate coagulation activation and enhanced brinolytic function. e level of the PAI-1/tPA complex, a novel brinolytic marker, increases during pregnancyassociated hypercoagulable states, vascular spasms and atherosclerotic states [7] ; therefore, identi cation of the PAI-1/tPA complex may provide valuable prognostic information with respect to patients with breast cancer [8] and myocardial infarction with manifested coronary heart disease [9] . Oral HRT, but not transdermal HRT, is associated with PAI activity and t-PA antigen levels that are lower than those found in postmenopausal HRT non-users. ese e ects of oral HRT may re ect a " rst-pass" e ect on hepatic PAI-1 synthesis [10] .
To date, the e ects of two commonly used postmenopausal hormone replacement therapy regimens, 17β-estradiol plus norethisterone acetate and 17β-estradiol plus drospirenone, on brinolytic activity remain unclear. e components of the brinolytic system may be in uenced by many individual factors, such as age, stress, hypertension, glucose intolerance, diabetes and surgical or natural menopause in humans. erefore, we used a rat model of surgical menopause to neutralize or eliminate the e ect of these confounding factors and investigate only the e ect of HRT.
In the present study, the e ects of ovariectomy (surgical menopause) and the aforementioned two HRT regimens on brinolytic activity were investigated in a surgical menopause rat model.
Materials and Methods
e experimental procedure was approved by Experimental Animal-Research and Breeding Laboratory, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey. Parameters and data regarding oxidative stress and brinolysis in the present study were derived from a previous study by our group [11] .
Chemicals and equipment
Chemicals and solvents used in the experiments were of highest purity and analytical grade. Deionized water was used in analytical procedures. All reagents were stored at +4°C. e reagents were maintained at equilibrium at room temperature for 30 min before use. All centrifugation procedures were performed using a Jouan G 412 centrifuge.
Experimental procedure
All e orts were made to minimize the number of animals used in the study. A total of 32 12 week old, sexually mature female Sprague-Dawley rats, each weighing 200-250 g, were used. All animals were kept in conventional wire-mesh cages with four rats per cage in a room with the temperature regulated at 21 ± 1°C, a humidity of 45-50%, and 12 h light/dark cycles with ad libitum access to food and water throughout the course of the experiment.
Animals were anesthetized by the administration of ketamine (50 mg/kg) and xylazine (10 mg/kg) into the marginal tail veins. e rats underwent either a bilateral ovariectomy or a sham surgical procedure via midline laparotomy incision under sterile conditions followed by appropriate closure of the incisions, as described elsewhere [11] .
Rats were randomly divided into four groups: (1) the sham-surgery group (n=8), (2) ovariectomy group (n=8), (3) ovariectomy group followed by oral lavage administration of daily 17β-estradiol (0.02 mg/kg/day) + norethisterone acetate (0.01 mg/kg/day) (Kliogest®; Novo Nordisk, Bagsvaerd, Denmark) (n=8), and (4) ovariectomy group followed by oral lavage administration of daily 17β-estradiol (0.01 mg/kg/day) + drospirenone (0.02 mg/kg/day) (Angeliq®; Schering AG, Berlin, Germany) (n=8).
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Blood-sample collection and processing
Blood samples were drawn in the fasting state and processed within 1 h of collection. Samples were collected in tubes containing lithium heparin, EDTA, or no additive depending on the nature of the analysis. For the determination of brinolytic parameters, plasma samples containing lithium heparin were stored at -80°C until required. All other routine clinicalchemistry parameters were determined on the day of collection using the Hitachi 704 auto-analyzer (Boehringer Mannheim, Tokyo, Japan).
Preparation of tissue samples
Brain tissue samples (except those from the cerebellum, pons and medulla oblongata) and liver tissues from the rats were immediately removed, washed in cooled 0.15 M NaCl, and placed on an ice-cold plate. Tissue samples were then immediately frozen in liquid N2 until experimentation. Tissue samples (200 mg) were homogenized manually in 2 ml of homogenizing bu er (100 mM KH2PO4-K2HPO4, pH 7.4, plus 0.1% (w/v) digitonin) in a glass homogenizer to avoid disruption of nuclear membranes. In this way, contamination by nucleic acids was minimized [12] . Homogenates obtained from the rats were centrifuged at 5000 × g for 10 min, and the various analytes were assayed using the supernatant fraction.
Assay of tPA, PAI-1 and tPA/PAI-1 levels
tPA, PAI-1, and tPA/PAI-1 levels in plasma and tissues (brain and liver) were measured using Assaypro ELISA kits according to the manufacturer's instructions (AssayMax ELISA kit; Assaypro, Win eld, MO, USA). Estradiol in serum was measured using the Chemiluminescent Microparticle Immunoassay (CMIA) and the Architect-i 2000 System (Abbott, Abbott Park, IL, USA). Total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels in serum were determined using the appropriate kits from Sigma Aldrich (St. Louis, MO, USA).
Statistical analysis
Data are expressed as means ± standard error of the mean (SEM) for eight animals per group. Di erences between groups were assessed by one-way analysis of variance (ANOVA) using the SPSS so ware package for Windows (SPSS Inc., Chicago, IL, USA). Post hoc testing was performed for inter-group comparisons using the least-signi cancedi erence (LSD) test. Post hoc tests were conducted using the Bonferroni-Dunn test. A probability value of less than 0.05 was deemed to indicate statistical signi cance for all comparisons.
Results
Routine clinical and biochemical parameters of the groups subjected to ovariectomy alone and ovariectomy plus both HRT regimens, as well as their respective controls (sham operated), are summarized in Table 1 . No allergic or gastrointestinal complications -such as hepatotoxicity -were observed during the study period. No mortality occurred. e 17β-estradiol + drospirenone group lost more weight than the 17β-estradiol + norhisterone acetate group, likely due to the natriuretic properties of drospirenone (Table 1 ). e information in Table 1 is identical to that included in a previous study by our group [11] .
Five weeks a er surgery, the serum E2 levels of shamoperated rats had not changed signi cantly, whereas the serum E2 levels decreased signi cantly in the ovariectomy group, con rming successful induction of surgical menopause (p < 0.001) ( Table 1) . Following 5 weeks' administration of 17β-estradiol + drospirenone (Angeliq®) and 17β-estradiol + norethisterone acetate (Kliogest®), the serum E2 levels were 220.13 ± 77.56 pg/ml and 162.38 ± 34.99 pg/ml, respectively (Table  1) . ese results con rmed that E2 replacement therapy was e ective in ovariectomized rats. In sham-operated rats, no change was noted in any of the parameters compared with the initial values (Table 1) .
In sham-operated rats, no change was observed in TC (mg/dl) (70.68 ± 10.23; 74.50 ± 8.02), HDL-C (mg/dl) (20.69 ± 1.97; 21.50 ± 1.05) and TG (mg/dl) (81.33 ± 8.64; 78.17 ± 11.39) levels compared with the initial preoperative values. Additionally, no change was noted in the plasma tPA, PAI-1, and PAI-1/tPA levels in sham-operated rats pre-and postoperatively. e plasma tPA, PAI, and tPA/PAI levels increased signi cantly (P < 0.001) in ovariectomized rats; however, the plasma tPA, PAI, and tPA/PAI levels were signicantly decreased in both groups that underwent HRT regimens compared with those in the ovariectomy group (Tables 2 and  3) . e liver tPA, PAI, and tPA/PAI levels were signi cantly higher in the ovariectomized rats than in the sham-operated rats (Table 4) ; however, these parameters were signi cantly decreased in both groups that received HRT compared with those in the ovariectomized group, but were higher than those in the sham group. Despite the signi cant changes in parameters in the liver tissues, no change was found in any of the parameters in brain tissues. 
Discussion
In the present study, two popular modern oral HRT regimens, which include two progesterogenic molecules (norethisterone acetate and drospirenone) combined with the same estrogen molecule, were used. Drospirenone is the rst synthetic progestin with anti-mineralocorticoid activity similar to natural progesterone itself [13] . Drospirenone is structurally related to the 17α-spirolactone used in contraceptive pills. Drospirenone also demonstrates clear anti-mineralocorticoid activity in the kidney, as re ected by elevated natriuresis [14] . is e ect is well established at dose levels that exert progestational and antiovulatory e ects, respectively, in rats and humans [15] . In our study, the drospirenone group lost more weight than the group that used norethisterone acetate as the progestagen. e cause of the weight loss may be the increased level of natriuresis; however, little is known of the e ects of this compound on brinolysis. Norethindrone acetate is a 19-nortestosteronederived progestin with potent e ects on minimizing estrogeninduced endometrial stimulation, even at very low doses [16] .
e available data from animal models suggest that norethindrone does not attenuate the anti-atherosclerotic e ects of estrogens [17, 18] . Most of the information from human studies concerning the metabolic e ects of norethindrone has been obtained using high doses -from 1 to 10 mg [19] ; thus, the impact of low doses of norethindrone on cardiovascular parameters should be investigated further.
Estrogen exerts bene cial e ects on blood lipids, lowdensity lipoprotein (LDL) oxidation, vascular function, and some aspects of the coagulation system [2] . e estrogen compound used most o en was a preparation of conjugated estrogens from equine sources; however, 17β-estradiol was used in our study. Orally-administered estrogens raise the levels of HDL-C and lower the levels of low-density lipoprotein cholesterol (LDL-C) [20, 21] , producing a lipid pro le similar to that of premenopausal females. e e ect of estrogen on coronary heart disease remains controversial. Levels of TC were found to increase a er ovariectomy, but decreased a er administration of norethisterone acetate and drospirenone. Additionally, HDL-C levels were increased in both the norethisterone acetate and drospirenone groups. is nding may explain why both the norethisterone acetate and drospirenone regimens have bene cial e ects on pathologies such as heart disease and arteriosclerosis [22] .
e hemostatic mechanism responsible for the proteolytic degradation of intravascular brin deposition is the brinolytic system. Both clinical and epidemiological data have suggested that reduced endogenous brinolytic activity, characterized by decreased t-PA antigen levels, increased PAI-1 antigen levels, and PAI-1 activity, is a major contributor to both the development and severity of atherothrombosis [23] [24] [25] [26] . Higher levels of PAI-1 were noted in postmenopausal than premenopausal women in the Framingham O spring Study [27] ; this increased level may, in part, account for the increased risk of atherosclerosis and its clinical consequences a er menopause. e e ect of combined HRT on brinolysis is also controversial, with reports of normal [28] and increased [29] levels of the D-dimer, a speci c marker of brinolysis. Postmenopausal hormonal therapy may stimulate the brinolytic system by increasing the concentrations of t-PA and lowering the levels of PAI-1. Estrogen administered in postmenopausal hormonal therapy a ects directly the biosynthesis and secretion of PAI-1 [30] ; however, the progestin component may reduce the benecial e ects of estrogen on the brinolytic system [31] . Ruszkowska et al. [32] reported that the route of administration of postmenopausal hormonal therapy had a signi cant e ect on the concentration of PAI-1:Ag in the blood. Higher levels of PAI-1:Ag were found in women who used transdermal postmenopausal hormonal therapy than in those who received oral postmenopausal hormonal therapy. Other studies [30] [31] [32] [33] [34] [35] [36] demonstrated that oral postmenopausal hormonal therapy signi cantly reduced the levels of PAI-1 (by up to 50%); however, no such signi cant change was associated with transdermal postmenopausal hormonal therapy.
A limited number of studies have reported con icting results regarding brinolytic activity in human and rats [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] . Additionally, no report on the in uence of norethisterone acetate and drospirenone on the tPA and PAI-1 levels in liver and brain tissue of rats has been published to date. Our study is the rst report on the e ects of these drugs on brinolytic activity: PAI-1 and tPA levels, as well as the PAI-1/tPA ratio, were signi cantly higher a er bilateral oophorectomy, suggesting an increase in brinolytic activity, particularly a er ovariectomy.
e cause may be stimulation of the release of PAI-1 by t-PA. Increased PAI-1 levels in menopause may reveal the risk of thrombotic cardiovascular disease, including coronary heart disease. e liver tPA and PAI levels were signi cantly higher in ovariectomized rats than in sham-operated rats. A er administration of drospirenone and norethisterone acetate in ovariectomized rats, the tPA, PAI, and tPA/PAI levels in liver tissue were decreased signi cantly. Both HRT regimens antagonized the increase in brinolytic activity that occurs a er ovariectomy (surgical menopause). HRT caused a decrease in the brinolytic activity rates in both plasma and liver tissue of ovariectomized rats. It seems clear that drospirenone decreases the PAI levels of liver tissue more e ectively than norethister- [36] showed that oral use of postmenopausal hormonal therapy resulted in stimulation of the synthesis of many proteins in the liver (including t-PA and PAI-1) and increased clearance in hepatocytes. Our results are consistent with those of Post et al. [36] . Coagulation and brinolysis may also in uence cardiovascular risk; however, the relationship of the lipid pro le to these processes in menopause is unclear. e signi cance of increased PAI-1 remains unclear; several observational studies reported high concentrations of PAI-1 to be a risk factor for cardiovascular disease, but the signi cance of PAI-1 as a predictor o en disappears a er adjusting for lipids and BMI [37] . e use of rat as model of surgically-induced menopause and the manner in which the data were presented here do have some limitations. Surgery itself may alter brinolytic activity through wound healing and other processes.
e e ects of sham surgery on brinolytic activity in this group were not evaluated this information, which would have served as an additional "baseline" was not available.
In conclusion, our results suggest that oral HRT demonstrates bene cial e ects on the menopause-mediated decrease in brinolytic activity. Short-term oral HRT seems to be associated with a shi in the procoagulant-anticoagulant balance towards a procoagulant state. e con icting results from human and animal studies of heart disease prevention by estrogens and progestins suggest the need for further investigation of nuclear hormone receptor function and interaction. Longterm, controlled, and prospective studies are needed to evaluate this hypothesis and con rm our ndings. Furthermore, studies including an increased number of rats and using other HRT protocols should be performed to con rm our suggestion that HRT has a protective e ect on brinolysis in ovariectomized rats.
